Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00045760 · ClinicalTrials.gov registry record · Phase 4
The Study of Drotrecogin Alfa (Activated) in a Subpopulation of Adult Patients With Severe Sepsis
A Phase 4 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 4
- Development phase
NCT00045760: Completed Phase 4 study, sponsored by Eli Lilly and Company.
NCT00045760 is a Phase 4 study that has completed, run by Eli Lilly and Company. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00045760, a Phase 4 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 4
- Development phase
Study Summary
Severe sepsis is defined as a systemic inflammatory response syndrome that results from infection and is associated with acute organ dysfunction. It usually results from bacterial infections, but it may occur in response to other pathogens, such as fungi, viruses, and parasites.
Interventions
- DRUG Drotrecogin alfa (activated)
Trial Details
| Field | Value |
|---|---|
| Start Date | 2002-09 |
| Phase | Phase 4 |
What the finished NCT00045760 record still lists
NCT00045760 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which Drotrecogin alfa (activated) is the first listed.
NCT00045760 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00045760 about?
NCT00045760 is a clinical study titled "The Study of Drotrecogin Alfa (Activated) in a Subpopulation of Adult Patients With Severe Sepsis". Severe sepsis is defined as a systemic inflammatory response syndrome that results from infection and is associated with acute organ dysfunction. It usually results from bacterial infections, but it may occur in response to other pathogens, such as fungi, viruses, and parasites.
What is the current status of trial NCT00045760?
This trial is currently completed. It is a Phase 4 study. The study started on 2002-09.
What interventions are being tested in trial NCT00045760?
The interventions under investigation include: Drotrecogin alfa (activated) (DRUG).
Who is sponsoring clinical trial NCT00045760?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia